NewAmsterdam Pharma Company NAMS Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's operating cash flow?
- NewAmsterdam Pharma Company (NAMS) reported operating cash flow of -$30.6M in Q1 2026.
- How has NewAmsterdam Pharma Company's operating cash flow changed year-over-year?
- NewAmsterdam Pharma Company's operating cash flow increased by 16.1% year-over-year, from -$36.47M to -$30.6M.
- What is the long-term trend for NewAmsterdam Pharma Company's operating cash flow?
- Over 4 years (2021 to 2025), NewAmsterdam Pharma Company's operating cash flow has grown at a 49.6% compound annual growth rate (CAGR), from -$29.51M to -$147.78M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.